1
|
Baydoun M, Boidin L, Leroux B, Vignion-Dewalle AS, Quilbe A, Grolez GP, Azaïs H, Frochot C, Moralès O, Delhem N. Folate Receptor Targeted Photodynamic Therapy: A Novel Way to Stimulate Anti-Tumor Immune Response in Intraperitoneal Ovarian Cancer. Int J Mol Sci 2023; 24:11288. [PMID: 37511049 PMCID: PMC10378870 DOI: 10.3390/ijms241411288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 06/20/2023] [Accepted: 06/30/2023] [Indexed: 07/30/2023] Open
Abstract
Photodynamic therapy (PDT) has shown improvements in cancer treatment and in the induction of a proper anti-tumor immune response. However, current photosensitizers (PS) lack tumor specificity, resulting in reduced efficacy and side effects in patients with intraperitoneal ovarian cancer (OC). In order to target peritoneal metastases of OC, which overexpress folate receptor (FRα) in 80% of cases, we proposed a targeted PDT using a PS coupled with folic acid. Herein, we applied this targeted PDT in an in vivo mouse model of peritoneal ovarian carcinomatosis. The efficacy of the treatment was evaluated in mice without and with human peripheral blood mononuclear cell (PBMC) reconstitution. When mice were reconstituted, using a fractionized PDT protocol led to a significantly higher decrease in the tumor growth than that obtained in the non-reconstituted mice (p = 0.0469). Simultaneously, an immune response was reflected by an increase in NK cells, and both CD4+ and CD8+ T cells were activated. A promotion in cytokines IFNγ and TNFα and an inhibition in cytokines TGFβ, IL-8, and IL-10 was also noticed. Our work showed that a fractionized FRα-targeted PDT protocol is effective for the treatment of OC and goes beyond local induction of tumor cell death, with the promotion of a subsequent anti-tumor response.
Collapse
Affiliation(s)
- Martha Baydoun
- Univ. Lille, Inserm, CHU Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, 59000 Lille, France
| | - Léa Boidin
- Univ. Lille, Inserm, CHU Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, 59000 Lille, France
| | - Bertrand Leroux
- Univ. Lille, Inserm, CHU Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, 59000 Lille, France
| | - Anne-Sophie Vignion-Dewalle
- Univ. Lille, Inserm, CHU Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, 59000 Lille, France
| | - Alexandre Quilbe
- Univ. Lille, Inserm, CHU Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, 59000 Lille, France
| | - Guillaume Paul Grolez
- Univ. Lille, Inserm, CHU Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, 59000 Lille, France
| | - Henri Azaïs
- Department of Gynecological and Breast Surgery and Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière University Hospital, 75013 Paris, France
| | - Céline Frochot
- Laboratoire des Réactions et Génie des Procédés (LRGP), CNRS-Université de Lorraine, 1 Rue Grandville, 54000 Nancy, France
| | - Olivier Moralès
- Univ. Lille, Inserm, CHU Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, 59000 Lille, France
- INSERM UMR9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, 59000 Lille, France
| | - Nadira Delhem
- Univ. Lille, Inserm, CHU Lille, U1189-ONCOTHAI-Assisted Laser Therapy and Immunotherapy for Oncology, 59000 Lille, France
| |
Collapse
|
2
|
Kumar A, Pecquenard F, Baydoun M, Quilbé A, Moralès O, Leroux B, Aoudjehane L, Conti F, Boleslawski E, Delhem N. An Efficient 5-Aminolevulinic Acid Photodynamic Therapy Treatment for Human Hepatocellular Carcinoma. Int J Mol Sci 2023; 24:10426. [PMID: 37445603 DOI: 10.3390/ijms241310426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Revised: 06/16/2023] [Accepted: 06/16/2023] [Indexed: 07/15/2023] Open
Abstract
Photodynamic therapy (PDT) is a two-stage treatment relying on cytotoxicity induced by photoexcitation of a nontoxic dye, called photosensitizer (PS). Using 5-aminolevulinic acid (5-ALA), the pro-drug of PS protoporphyrin IX, we investigated the impact of PDT on hepatocellular carcinoma (HCC). Optimal 5-ALA PDT dose was determined on three HCC cell lines by analyzing cell death after treatment with varying doses. HCC-patient-derived tumor hepatocytes and healthy donor liver myofibroblasts were treated with optimal 5-ALA PDT doses. The proliferation of cancer cells and healthy donor immune cells cultured with 5-ALA-PDT-treated conditioned media was analyzed. Finally, therapy efficacy on humanized SCID mice model of HCC was investigated. 5-ALA PDT induced a dose-dependent decrease in viability, with an up-to-four-fold reduction in viability of patient tumor hepatocytes. The 5-ALA PDT treated conditioned media induced immune cell clonal expansion. 5-ALA PDT has no impact on myofibroblasts in terms of viability, while their activation decreased cancer cell proliferation and reduced the tumor growth rate of the in vivo model. For the first time, 5-ALA PDT has been validated on primary patient tumor hepatocytes and donor healthy liver myofibroblasts. 5-ALA PDT may be an effective anti-HCC therapy, which might induce an anti-tumor immune response.
Collapse
Affiliation(s)
- Abhishek Kumar
- Univ. Lille, Inserm, CHU Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France
| | - Florian Pecquenard
- Univ. Lille, Inserm, CHU Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France
- CHU Lille, Service de Chirurgie Digestive et Transplantations, Université de Lille, F-59037 Lille, France
| | - Martha Baydoun
- Univ. Lille, Inserm, CHU Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France
| | - Alexandre Quilbé
- Univ. Lille, Inserm, CHU Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France
| | - Olivier Moralès
- Univ. Lille, Inserm, CHU Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France
- Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France
| | - Bertrand Leroux
- Univ. Lille, Inserm, CHU Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France
| | - Lynda Aoudjehane
- INSERM, Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, F-75013 Paris, France
- INSERM, Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, F-75012 Paris, France
| | - Filomena Conti
- INSERM, Institute of Cardiometabolism and Nutrition (ICAN), Sorbonne Université, F-75013 Paris, France
- INSERM, Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, F-75012 Paris, France
- Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Department of Medical Liver Transplantation, F-75013 Paris, France
| | - Emmanuel Boleslawski
- Univ. Lille, Inserm, CHU Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France
- CHU Lille, Service de Chirurgie Digestive et Transplantations, Université de Lille, F-59037 Lille, France
| | - Nadira Delhem
- Univ. Lille, Inserm, CHU Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France
| |
Collapse
|
3
|
Khaled S, Gantois N, Ly AT, Senghor S, Even G, Dautel E, Dejager R, Sawant M, Baydoun M, Benamrouz-Vanneste S, Chabé M, Ndiaye S, Schacht AM, Certad G, Riveau G, Viscogliosi E. Prevalence and Subtype Distribution of Blastocystis sp. in Senegalese School Children. Microorganisms 2020; 8:microorganisms8091408. [PMID: 32932661 PMCID: PMC7564003 DOI: 10.3390/microorganisms8091408] [Citation(s) in RCA: 53] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Revised: 09/07/2020] [Accepted: 09/10/2020] [Indexed: 12/12/2022] Open
Abstract
Blastocystis sp. is an enteric protozoan that frequently colonizes humans and many animals. Despite impacting on human health, data on the prevalence and subtype (ST) distribution of Blastocystis sp. remain sparse in Africa. Accordingly, we performed the first multicenter and largest epidemiological survey ever conducted on Blastocystis sp. for this continent. A total of 731 stool samples collected from healthy school children living in 10 villages of the northwestern region of Senegal were tested for the presence of Blastocystis sp. by real-time polymerase chain reaction followed by subtyping of positive samples. Considerable variation in prevalence between villages (51.7 to 100%) was evident with the overall prevalence being 80.4%. Mixed infections were identified in 23% of positive individuals. Among 453 school children with a single infection, ST2 was predominant, followed by ST1, ST3, ST7, ST10, and ST14; this is the first report of ST10 and ST14 in humans. Genetic polymorphisms were evident at the intra-ST level with the identification of numerous ST1 to ST3 genotypes. ST1 showed the greatest intra-ST diversity followed by ST2 and ST3. The prevalence and distribution of STs and genotypes varied among target villages, pointing to several potential infection sources, including human-to-human, zoonotic, and waterborne transmission.
Collapse
Affiliation(s)
- Salma Khaled
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
| | - Nausicaa Gantois
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
| | - Amadou Tidjani Ly
- Biomedical Research Center Espoir Pour La Santé (BRC-EPLS), BP 226 Saint-Louis, Senegal; (A.T.L.); (S.S.)
| | - Simon Senghor
- Biomedical Research Center Espoir Pour La Santé (BRC-EPLS), BP 226 Saint-Louis, Senegal; (A.T.L.); (S.S.)
| | - Gaël Even
- Gènes Diffusion, F-59501 Douai, France;
- PEGASE-Biosciences (Plateforme d’Expertises Génomiques Appliquées aux Sciences Expérimentales), Institut Pasteur de Lille, F-59000 Lille, France
| | - Ellena Dautel
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
| | - Romane Dejager
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
| | - Manasi Sawant
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
| | - Martha Baydoun
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
| | - Sadia Benamrouz-Vanneste
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
- Laboratoire Ecologie et Biodiversité, Institut Catholique de Lille, Faculté de Gestion Economie et Sciences, F-59000 Lille, France
| | - Magali Chabé
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
| | - Seynabou Ndiaye
- Région Médicale de Saint-Louis, MSAS, BP 226 Saint-Louis, Senegal;
| | - Anne-Marie Schacht
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
- Biomedical Research Center Espoir Pour La Santé (BRC-EPLS), BP 226 Saint-Louis, Senegal; (A.T.L.); (S.S.)
| | - Gabriela Certad
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
- Délégation à la Recherche Clinique et à l’Innovation, Groupement des Hôpitaux de l’Institut Catholique de Lille, F-59000 Lille, France
| | - Gilles Riveau
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
- Biomedical Research Center Espoir Pour La Santé (BRC-EPLS), BP 226 Saint-Louis, Senegal; (A.T.L.); (S.S.)
| | - Eric Viscogliosi
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
- Correspondence:
| |
Collapse
|
4
|
Baydoun M, Moralès O, Frochot C, Ludovic C, Leroux B, Thecua E, Ziane L, Grabarz A, Kumar A, de Schutter C, Collinet P, Azais H, Mordon S, Delhem N. Photodynamic Therapy Using a New Folate Receptor-Targeted Photosensitizer on Peritoneal Ovarian Cancer Cells Induces the Release of Extracellular Vesicles with Immunoactivating Properties. J Clin Med 2020; 9:jcm9041185. [PMID: 32326210 PMCID: PMC7230754 DOI: 10.3390/jcm9041185] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Revised: 04/11/2020] [Accepted: 04/12/2020] [Indexed: 12/12/2022] Open
Abstract
Often discovered at an advanced stage, ovarian cancer progresses to peritoneal carcinoma, which corresponds to the invasion of the serosa by multiple tumor implants. The current treatment is based on the combination of chemotherapy and tumor cytoreduction surgery. Despite the progress and standardization of surgical techniques combined with effective chemotherapy, post-treatment recurrences affect more than 60% of women in remission. Photodynamic therapy (PDT) has been particularly indicated for the treatment of superficial lesions on large surfaces and appears to be a relevant candidate for the treatment of microscopic intraperitoneal lesions and non-visible lesions. However, the impact of this therapy on immune cells remains unclear. Hence, the objective of this study is to validate the efficacy of a new photosensitizer [pyropheophorbide a-polyethylene glycol-folic acid (PS)] on human ovarian cancer cells and to assess the impact of the secretome of PDT-treated cells on human peripheral blood mononuclear cells (PBMC). We show that PS, upon illumination, can induce cell death of different ovarian tumor cells. Furthermore, PDT using this new PS seems to favor activation of the immune response by inducing the secretion of effective cytokines and inhibiting the pro-inflammatory and immunosuppressive ones, as well as releasing extracellular vesicles (EVs) prone to activating immune cells. Finally, we show that PDT can activate CD4+ and CD8+ T cells, resulting in a potential immunostimulating process. The results of this pilot study therefore indicate that PS-PDT treatment may not only be effective in rapidly and directly destroying target tumor cells but also promote the activation of an effective immune response; notably, by EVs. These data thus open up good prospects for the treatment of micrometastases of intraperitoneal ovarian carcinosis which are currently inoperable.
Collapse
Affiliation(s)
- Martha Baydoun
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
| | - Olivier Moralès
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
- CNRS UMS 3702, Institut de Biologie de Lille, 59 021 Lille, France
| | - Céline Frochot
- LGRGP, UMR-CNRS 7274, University of Lorraine, 54 001 Nancy, France; (C.F.); (C.L.)
| | - Colombeau Ludovic
- LGRGP, UMR-CNRS 7274, University of Lorraine, 54 001 Nancy, France; (C.F.); (C.L.)
| | - Bertrand Leroux
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
| | - Elise Thecua
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
| | - Laurine Ziane
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
| | - Anne Grabarz
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
- Unité de Gynécologie-Obstétrique, Hôpital Jeanne de Flandre, 59 000 CHU Lille, France
| | - Abhishek Kumar
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
| | - Clémentine de Schutter
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
| | - Pierre Collinet
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
- Unité de Gynécologie-Obstétrique, Hôpital Jeanne de Flandre, 59 000 CHU Lille, France
| | - Henri Azais
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
- Service de Chirurgie et Cancérologie Gynécologique et Mammaire, Hôpital de la Pitié-Salpêtrière, AP-HP, 75 013 Paris, France
| | - Serge Mordon
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
- Correspondence: (S.M.); (N.D.); Tel./Fax: +33-32044-6708 (S.M.); Tel.: +33-3208-71253/1251 (N.D.); Fax: +33-32087-1019 (N.D.)
| | - Nadira Delhem
- Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI–Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France; (M.B.); (O.M.); (B.L.); (E.T.); (L.Z.); (A.G.); (A.K.); (C.d.S.); (P.C.); (H.A.)
- Correspondence: (S.M.); (N.D.); Tel./Fax: +33-32044-6708 (S.M.); Tel.: +33-3208-71253/1251 (N.D.); Fax: +33-32087-1019 (N.D.)
| |
Collapse
|
5
|
Gantois N, Lamot A, Seesao Y, Creusy C, Li LL, Monchy S, Benamrouz-Vanneste S, Karpouzopoulos J, Bourgain JL, Rault C, Demaret F, Baydoun M, Chabé M, Fréalle E, Aliouat-Denis CM, Gay M, Certad G, Viscogliosi E. First Report on the Prevalence and Subtype Distribution of Blastocystis sp. in Edible Marine Fish and Marine Mammals: A Large Scale-Study Conducted in Atlantic Northeast and on the Coasts of Northern France. Microorganisms 2020; 8:microorganisms8030460. [PMID: 32213897 PMCID: PMC7144014 DOI: 10.3390/microorganisms8030460] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 03/03/2020] [Accepted: 03/22/2020] [Indexed: 12/18/2022] Open
Abstract
Blastocystis is frequently identified in humans and animal hosts and exhibits a large genetic diversity with the identification of 17 subtypes (STs). Despite its zoonotic potential, its prevalence and ST distribution in edible marine fish and marine mammals remain unknown. A large-scale survey was thus conducted by screening 345 fish caught in Atlantic Northeast and 29 marine mammals stranded on the coasts of northern France for the presence of the parasite using real-time Polymerase Chain Reaction PCR. The prevalence of the parasite was about 3.5% in marine fish. These animals were mostly colonized by poikilotherm-derived isolates not identified in humans and corresponding to potential new STs, indicating that fish are natural hosts of Blastocystis. Marine fishes are also carriers of human STs and represent a likely limited source of zoonotic transmission. 13.8% of the marine mammals tested were colonized and 6 different STs were identified including 3 potential new STs. The risk of zoonotic transmission through marine mammals is insignificant due to the lack of repeated contact with humans. The present survey represents the first data regarding the prevalence and ST distribution of Blastocystis in marine fish and marine mammals and provides new insights into its genetic diversity, host range and transmission.
Collapse
Affiliation(s)
- Nausicaa Gantois
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 – UMR 9017 – CIIL – Centre d’Infection et d’Immunité de Lille, F-59000 Lille, France; (N.G.); (A.L.); (S.B.-V.); (M.B.); (M.C.); (E.F.); (C.-M.A.-D.); (G.C.)
| | - Angélique Lamot
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 – UMR 9017 – CIIL – Centre d’Infection et d’Immunité de Lille, F-59000 Lille, France; (N.G.); (A.L.); (S.B.-V.); (M.B.); (M.C.); (E.F.); (C.-M.A.-D.); (G.C.)
| | - Yuwalee Seesao
- French Agency for Food, Environmental and Occupational Health and Safety (Anses), Laboratory for Food Safety, F-62200 Boulogne-sur-mer, France; (Y.S.); (L.-L.L.); (M.G.)
| | - Colette Creusy
- Service d’Anatomie et de Cytologie Pathologiques, Groupement des Hôpitaux de l’Institut Catholique de Lille (GHICL), F-59000 Lille, France;
| | - Luen-Luen Li
- French Agency for Food, Environmental and Occupational Health and Safety (Anses), Laboratory for Food Safety, F-62200 Boulogne-sur-mer, France; (Y.S.); (L.-L.L.); (M.G.)
- Univ. Littoral Côte d’Opale, CNRS, Univ. Lille, UMR 8187, LOG, Laboratoire d’Océanologie et de Géosciences, F-62930 Wimereux, France;
| | - Sébastien Monchy
- Univ. Littoral Côte d’Opale, CNRS, Univ. Lille, UMR 8187, LOG, Laboratoire d’Océanologie et de Géosciences, F-62930 Wimereux, France;
| | - Sadia Benamrouz-Vanneste
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 – UMR 9017 – CIIL – Centre d’Infection et d’Immunité de Lille, F-59000 Lille, France; (N.G.); (A.L.); (S.B.-V.); (M.B.); (M.C.); (E.F.); (C.-M.A.-D.); (G.C.)
- Laboratoire Ecologie et Biodiversité, Faculté de Gestion Economie et Sciences, Institut Catholique de Lille, F-59000 Lille, France
| | - Jacky Karpouzopoulos
- Coordination Mammalogique du Nord de la France, Groupe Mammifères Marins, F-62850 Alembon, France; (J.K.); (J.-L.B.); (C.R.)
| | - Jean-Luc Bourgain
- Coordination Mammalogique du Nord de la France, Groupe Mammifères Marins, F-62850 Alembon, France; (J.K.); (J.-L.B.); (C.R.)
| | - Célia Rault
- Coordination Mammalogique du Nord de la France, Groupe Mammifères Marins, F-62850 Alembon, France; (J.K.); (J.-L.B.); (C.R.)
| | - Fabien Demaret
- Observatoire PELAGIS - UMS 3462, La Rochelle Université/CNRS, F-17000 La Rochelle, France;
| | - Martha Baydoun
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 – UMR 9017 – CIIL – Centre d’Infection et d’Immunité de Lille, F-59000 Lille, France; (N.G.); (A.L.); (S.B.-V.); (M.B.); (M.C.); (E.F.); (C.-M.A.-D.); (G.C.)
| | - Magali Chabé
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 – UMR 9017 – CIIL – Centre d’Infection et d’Immunité de Lille, F-59000 Lille, France; (N.G.); (A.L.); (S.B.-V.); (M.B.); (M.C.); (E.F.); (C.-M.A.-D.); (G.C.)
| | - Emilie Fréalle
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 – UMR 9017 – CIIL – Centre d’Infection et d’Immunité de Lille, F-59000 Lille, France; (N.G.); (A.L.); (S.B.-V.); (M.B.); (M.C.); (E.F.); (C.-M.A.-D.); (G.C.)
| | - Cécile-Marie Aliouat-Denis
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 – UMR 9017 – CIIL – Centre d’Infection et d’Immunité de Lille, F-59000 Lille, France; (N.G.); (A.L.); (S.B.-V.); (M.B.); (M.C.); (E.F.); (C.-M.A.-D.); (G.C.)
| | - Mélanie Gay
- French Agency for Food, Environmental and Occupational Health and Safety (Anses), Laboratory for Food Safety, F-62200 Boulogne-sur-mer, France; (Y.S.); (L.-L.L.); (M.G.)
| | - Gabriela Certad
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 – UMR 9017 – CIIL – Centre d’Infection et d’Immunité de Lille, F-59000 Lille, France; (N.G.); (A.L.); (S.B.-V.); (M.B.); (M.C.); (E.F.); (C.-M.A.-D.); (G.C.)
- Délégation à la Recherche Clinique et à l’Innovation, Groupement des Hôpitaux de l’Institut Catholique de Lille, F-59000 Lille, France
| | - Eric Viscogliosi
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 – UMR 9017 – CIIL – Centre d’Infection et d’Immunité de Lille, F-59000 Lille, France; (N.G.); (A.L.); (S.B.-V.); (M.B.); (M.C.); (E.F.); (C.-M.A.-D.); (G.C.)
- Correspondence:
| |
Collapse
|
6
|
Safatly L, Baydoun M, Alipour M, Al-Takach A, Atab K, Al-Husseini M, El-Hajj A, Ghaziri H. Detection and classification of landmines using machine learning applied to metal detector data. J EXP THEOR ARTIF IN 2020. [DOI: 10.1080/0952813x.2020.1735529] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- L. Safatly
- Electrical and Computer Engineering Department, American University of Beirut, Beirut, Lebanon
| | - M. Baydoun
- Beirut Research and Innovation Center, Lebanese Center for Studies and Research, Beirut, Lebanon
| | - M. Alipour
- Beirut Research and Innovation Center, Lebanese Center for Studies and Research, Beirut, Lebanon
| | - A. Al-Takach
- Beirut Research and Innovation Center, Lebanese Center for Studies and Research, Beirut, Lebanon
| | - K. Atab
- Beirut Research and Innovation Center, Lebanese Center for Studies and Research, Beirut, Lebanon
| | - M. Al-Husseini
- Beirut Research and Innovation Center, Lebanese Center for Studies and Research, Beirut, Lebanon
| | - A. El-Hajj
- Electrical and Computer Engineering Department, American University of Beirut, Beirut, Lebanon
| | - H. Ghaziri
- Beirut Research and Innovation Center, Lebanese Center for Studies and Research, Beirut, Lebanon
| |
Collapse
|
7
|
Azaïs H, Rebahi C, Baydoun M, Serouart B, Ziane L, Moralès O, Frochot C, Colombeau L, Thécua E, Collinet P, Delhem N, Mordon S. A global approach for the development of photodynamic therapy of peritoneal metastases regardless of their origin. Photodiagnosis Photodyn Ther 2020; 30:101683. [PMID: 32061747 DOI: 10.1016/j.pdpdt.2020.101683] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2019] [Revised: 01/14/2020] [Accepted: 02/03/2020] [Indexed: 02/04/2023]
Abstract
Surgical management of peritoneal metastases raises the problem of the theoretical spread of the entire peritoneal surface. Intraperitoneal photodynamic therapy (IntraPDT) has been limited by the lack of specificity of photosensitizers (PS) and difficulties to bring light into the abdominal cavity. Recent data in ovarian cancer may give development opportunities for IntraPDT. Intraperitoneal PDT could be an option but the level of evidence of research in this topic must increase. Our opinion is that the most important is to have a realistic idea of what we can objectively expect from PDT and the feasibility of its daily application. At the time of personalized medicine, it is mandatory to select population eligible for a targeted PS administration and who could benefit from the process. The design of a specific PS for each subtype of cancers seems essential to avoid side effects on healthy tissue. On the contrary, our progress on lighting solutions can be beneficial for all patients with an indication of IntraPDT regardless of the origin of PM. A common lighting system developed for all cancers eligible for IntraPDT could be adapted with light source of specific wavelength to activate dedicated PS.
Collapse
Affiliation(s)
- Henri Azaïs
- Univ. Lille. Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, Lille, France.
| | - Christie Rebahi
- Univ. Lille. Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, Lille, France
| | - Martha Baydoun
- CNRS, UMR8161, Institut de Biologie de Lille, University of Lille, Institut Pasteur de Lille, France
| | - Benjamin Serouart
- Univ. Lille. Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, Lille, France
| | - Laurine Ziane
- Univ. Lille. Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, Lille, France
| | - Olivier Moralès
- CNRS, UMR8161, Institut de Biologie de Lille, University of Lille, Institut Pasteur de Lille, France
| | - Céline Frochot
- LGRGP, UMR-CNRS 7274, University of Lorraine, Nancy, France
| | | | - Elise Thécua
- Univ. Lille. Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, Lille, France
| | - Pierre Collinet
- Univ. Lille. Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, Lille, France; Department of Gynecologic Surgery - University Hospital, Lille, France
| | - Nadira Delhem
- CNRS, UMR8161, Institut de Biologie de Lille, University of Lille, Institut Pasteur de Lille, France
| | - Serge Mordon
- Univ. Lille. Inserm, CHU Lille, U1189, ONCO-THAI- Image Assisted Laser Therapy for Oncology, Lille, France
| |
Collapse
|
8
|
Baydoun M, Treizeibré A, Follet J, Benamrouz Vanneste S, Creusy C, Dercourt L, Delaire B, Mouray A, Viscogliosi E, Certad G, Senez V. An Interphase Microfluidic Culture System for the Study of Ex Vivo Intestinal Tissue. Micromachines (Basel) 2020; 11:E150. [PMID: 32019215 PMCID: PMC7074597 DOI: 10.3390/mi11020150] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/13/2019] [Revised: 01/21/2020] [Accepted: 01/28/2020] [Indexed: 11/22/2022]
Abstract
Ex vivo explant culture models offer unique properties to study complex mechanisms underlying tissue growth, renewal, and disease. A major weakness is the short viability depending on the biopsy origin and preparation protocol. We describe an interphase microfluidic culture system to cultivate full thickness murine colon explants which keeps morphological structures of the tissue up to 192 h. The system was composed of a central well on top of a porous membrane supported by a microchannel structure. The microfluidic perfusion allowed bathing the serosal side while preventing immersion of the villi. After eight days, up to 33% of the samples displayed no histological abnormalities. Numerical simulation of the transport of oxygen and glucose provided technical solutions to improve the functionality of the microdevice.
Collapse
Affiliation(s)
- Martha Baydoun
- Univ. Lille, CNRS, ISEN-YNCREA, UMR 8520-IEMN, F-59000 Lille, France
- ISA-YNCREA Hauts de France, F-59000 Lille, France
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9107-CIIL-Centre d’Infection et d’Immunité de Lille, F-59019 Lille, France
| | | | - Jérôme Follet
- Univ. Lille, CNRS, ISEN-YNCREA, UMR 8520-IEMN, F-59000 Lille, France
- ISA-YNCREA Hauts de France, F-59000 Lille, France
| | - Sadia Benamrouz Vanneste
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9107-CIIL-Centre d’Infection et d’Immunité de Lille, F-59019 Lille, France
- Laboratoire Ecologie et Biodiversité, Unité de Recherche Smart and Sustainable Cities, Faculté de Gestion Economie et Sciences, Institut Catholique de Lille, F-59800 Lille, France
| | - Colette Creusy
- Service d’Anatomie et de Cytologie Pathologiques, Groupement des Hôpitaux de l’Université Catholique de Lille, 59000 Lille, France
| | - Lucie Dercourt
- CNRS, Univ. Tokyo, UMI 2820 — LIMMS, F-59000 Lille, France
| | - Baptiste Delaire
- Service d’Anatomie et de Cytologie Pathologiques, Groupement des Hôpitaux de l’Université Catholique de Lille, 59000 Lille, France
| | - Anthony Mouray
- Plateforme d’Expérimentations et de Hautes Technologies Animales, Institut Pasteur de Lille Lille, 59019 Lille, France
| | - Eric Viscogliosi
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9107-CIIL-Centre d’Infection et d’Immunité de Lille, F-59019 Lille, France
| | - Gabriela Certad
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9107-CIIL-Centre d’Infection et d’Immunité de Lille, F-59019 Lille, France
- Délégation à la Recherche Clinique et à l’Innovation, Groupement des Hôpitaux de l’Institut Catholique de Lille (GHICL), Faculté de Médecine et Maïeutique, Université Catholique de Lille, 59800 Lille, France
| | - Vincent Senez
- Univ. Lille, CNRS, ISEN-YNCREA, UMR 8520-IEMN, F-59000 Lille, France
- CNRS, Univ. Tokyo, UMI 2820 — LIMMS, F-59000 Lille, France
| |
Collapse
|
9
|
Greige S, El Safadi D, Khaled S, Gantois N, Baydoun M, Chemaly M, Benamrouz-Vanneste S, Chabé M, Osman M, Certad G, Hamze M, Viscogliosi E. First report on the prevalence and subtype distribution of Blastocystis sp. in dairy cattle in Lebanon and assessment of zoonotic transmission. Acta Trop 2019; 194:23-29. [PMID: 30878470 DOI: 10.1016/j.actatropica.2019.02.013] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Revised: 02/06/2019] [Accepted: 02/12/2019] [Indexed: 02/07/2023]
Abstract
Blastocystis sp. is frequently identified in a wide range of animal hosts, including bovids. Because of its burden and zoonotic potential, this parasite has been sought in domestic cattle from various countries, since this livestock may also represent a possible reservoir of human infection. However, epidemiological data regarding the prevalence and ST distribution of Blastocystis sp. in this animal group is lacking in Lebanon. Therefore, faecal samples were collected from a total of 254 dairy cattle raised on 55 farms located in the North Lebanon region and screened for the presence of the parasite by quantitative real-time PCR. The overall prevalence of Blastocystis sp. was shown to reach 63.4% in cattle livestock. Sequence analysis of positive samples indicated the presence of seven STs, with predominance of ST10 (44.0%) and ST14 (36.8%) and lower proportions of ST2 (8.0%), ST1 (7.2%), ST5 (2.4%), ST3 and ST7 (0.8% each). This survey was the first conducted worldwide reporting ST2 and ST7 in domestic cattle and confirmed that ST10 and ST14 represent cattle-adapted STs in view of their high prevalence. Faecal samples from in-contact dairy farmers and patients hospitalised in the same Lebanese governorate who reported no contact with cattle livestock were also analysed for the presence of Blastocystis sp. The same three STs were identified in both human cohorts, with predominance of ST3, followed either by ST1 or ST2 depending of the group. No other STs, including ST10 or ST14, have been reported. Moreover, even though ST1, ST2 and ST3 were found to be common to dairy cattle and farmers cohorts, only one ST3 isolate showed 100% sequence identity between both hosts. Consequently, the presence and low prevalence of ST1, ST2, ST3, ST5 and ST7 identified herein in domestic cattle, most of which exhibit low host specificity, could be derived from occasional direct exposure to faecal material from human and non-human hosts or by ingestion of contaminated drinking water or food in the enclosure of the farms. Together with the absence of ST10 and ST14 in the human population, these data suggest that cattle play a negligible role as zoonotic reservoirs of Blastocystis sp.
Collapse
Affiliation(s)
- Stéphanie Greige
- Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cedex, France; Laboratoire Microbiologie Santé et Environnement (LMSE), Ecole Doctorale des Sciences et de Technologie, Faculté de Santé Publique, Université Libanaise, Rue Mitein, Tripoli, Lebanon
| | - Dima El Safadi
- Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cedex, France; Laboratoire Microbiologie Santé et Environnement (LMSE), Ecole Doctorale des Sciences et de Technologie, Faculté de Santé Publique, Université Libanaise, Rue Mitein, Tripoli, Lebanon
| | - Salma Khaled
- Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cedex, France; Laboratoire Microbiologie Santé et Environnement (LMSE), Ecole Doctorale des Sciences et de Technologie, Faculté de Santé Publique, Université Libanaise, Rue Mitein, Tripoli, Lebanon
| | - Nausicaa Gantois
- Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cedex, France
| | - Martha Baydoun
- Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cedex, France
| | - Marianne Chemaly
- ANSES, Ploufragan-Plouzané Laboratory, Hygiene and Quality of Poultry and Pig Products Unit, Bretagne-Loire University, Ploufragan, France
| | - Sadia Benamrouz-Vanneste
- Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cedex, France
| | - Magali Chabé
- Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cedex, France
| | - Marwan Osman
- Laboratoire Microbiologie Santé et Environnement (LMSE), Ecole Doctorale des Sciences et de Technologie, Faculté de Santé Publique, Université Libanaise, Rue Mitein, Tripoli, Lebanon
| | - Gabriela Certad
- Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cedex, France; Département de la Recherche Médicale, Groupement des Hôpitaux de l'Institut Catholique de Lille, Faculté de Médecine et Maïeutique, Université Catholique de Lille, 51 Boulevard de Belfort, 59000 Lille, France
| | - Monzer Hamze
- Laboratoire Microbiologie Santé et Environnement (LMSE), Ecole Doctorale des Sciences et de Technologie, Faculté de Santé Publique, Université Libanaise, Rue Mitein, Tripoli, Lebanon
| | - Eric Viscogliosi
- Université de Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cedex, France.
| |
Collapse
|
10
|
Barton D, Brooks T, Cieslak A, Elkins G, Clark P, Baydoun M, Smith A, VanPoznak C. Abstract P1-12-04: Preliminary evaluation of a mind-body intervention to improve body and/or self-image: A phase II randomized trial. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-12-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The number of cancer survivors is growing and expected to be 18.9 million by 2024. Addressing survivorship issues, such as sexual health, are a critical part of health promotion. Women diagnosed with breast or gynecologic cancer can experience distressing changes in their self and/or body image, which affects their sexual health. This study evaluates hypnosis compared to progressive muscle relaxation (PMR) to improve self/body image in order to improve sexuality.
Methods: Women with a history of breast or gynecologic cancer, who also report negative body image changes, were randomized in a 2:1 fashion to a 6-week intervention of hypnotic relaxation or PMR. Both intervention arms consisted of three 30-minute sessions delivered face-to-face by a trained therapist, one every two weeks, along with home practice using a CD. The primary outcome was impact of treatment on body image using the Impact of Treatment Scale (ITS). Secondary outcomes included mood (Positive/Negative Affect Scale-PANAS), sexual satisfaction (PROMIS satisfaction), and perceived change (Global Impression of Change Scale -GCIS). Outcomes were measured at baseline and 6 weeks except for the GCIS measured only at 6 weeks. A series of independent samples t-tests were used to compare changes in outcome measures between arms. The intention-to-treat principle was applied.
Results: The final randomized sample consisted of 87 women. There was no statistically significant difference (p=.15) in the change in ITS between groups at 6 weeks, with both groups significantly improving (within group effect size Cohen's d .49 - .75). There were non-significant differences between groups on secondary outcomes. Change from baseline for positive affect (PANAS) was 1.7 in the hypnosis group and 3.8 in the PMR group while negative affect change was very similar being about 2.8 in both groups. Change from baseline for the PROMIS general sexual satisfaction scale was 1.5 in the hypnosis group and 1.3 in the PMR group. On the GCIS at 6 weeks, 42% of the hypnosis group reported moderate to very much improvement on self/body image (GCIS) while only 32% of the PMR group reported this level of improvement; and 36% of the hypnosis group versus 11% of the PMR group reported moderate to very much improvement in their sexuality.
Implications: The stress relieving strategies applied in this study may contribute substantially to decreasing the distress of the cancer experience related to altered self/body image and sexuality. The variable improvement across domains suggests that hypnosis and PMR may work in different ways, mechanistically. Further mechanistic studies of interventions to optimally promote survivorship health are warranted.
Citation Format: Barton D, Brooks T, Cieslak A, Elkins G, Clark P, Baydoun M, Smith A, VanPoznak C. Preliminary evaluation of a mind-body intervention to improve body and/or self-image: A phase II randomized trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-12-04.
Collapse
Affiliation(s)
- D Barton
- University of Michigan, Ann Arbor, MI; Baylor University, Waco, TX
| | - T Brooks
- University of Michigan, Ann Arbor, MI; Baylor University, Waco, TX
| | - A Cieslak
- University of Michigan, Ann Arbor, MI; Baylor University, Waco, TX
| | - G Elkins
- University of Michigan, Ann Arbor, MI; Baylor University, Waco, TX
| | - P Clark
- University of Michigan, Ann Arbor, MI; Baylor University, Waco, TX
| | - M Baydoun
- University of Michigan, Ann Arbor, MI; Baylor University, Waco, TX
| | - A Smith
- University of Michigan, Ann Arbor, MI; Baylor University, Waco, TX
| | - C VanPoznak
- University of Michigan, Ann Arbor, MI; Baylor University, Waco, TX
| |
Collapse
|
11
|
Baydoun M, Safatly L, Walsh J, Abou Hassan O, Jaroudi W, El Hajj A, Ghaziri H, Isma'eel H. PO086 Machine Learning Approaches Improve Noninvasive Prediction of Ischemic From Non-Ischemic Cardiomyopathies. Glob Heart 2018. [DOI: 10.1016/j.gheart.2018.09.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
12
|
Osman M, Benamrouz S, Guyot K, Baydoun M, Frealle E, Chabe M, Gantois N, Delaire B, Goffard A, Aoun A, Jurdi N, Dabboussi F, Even G, Slomianny C, Gosset P, Hamze M, Creusy C, Viscogliosi E, Certad G. High association of Cryptosporidium spp. infection with colon adenocarcinoma in Lebanese patients. PLoS One 2017; 12:e0189422. [PMID: 29261714 PMCID: PMC5736188 DOI: 10.1371/journal.pone.0189422] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2017] [Accepted: 11/24/2017] [Indexed: 11/29/2022] Open
Abstract
Background The association between Cryptosporidium and human colon cancer has been reported in different populations. However, this association has not been well studied. In order to add new strong arguments for a probable link between cryptosporidiosis and colon human cancer, the aim of this study was to determine prevalence and to identify species of Cryptosporidium among Lebanese patients. Methodology and principal findings Overall, 218 digestive biopsies were collected in Tripoli, Lebanon, from three groups of patients: (i) patients with recently diagnosed colon intraepithelial neoplasia/adenocarcinoma before any treatment (n = 72); (ii) patients with recently diagnosed stomach intraepithelial neoplasia/adenocarcinoma before any treatment (n = 21); and (iii) patients without digestive intraepithelial neoplasia/adenocarcinoma but with persistent digestive symptoms (n = 125). DNA extraction was performed from paraffin-embedded tissue. The presence of the parasite in tissues was confirmed by PCR, microscopic observation and immunofluorescence analysis. We identified a high rate (21%) of Cryptosporidium presence in biopsies from Lebanese patients with recently diagnosed colonic neoplasia/adenocarcinoma before any treatment. This prevalence was significantly higher compared to 7% of Cryptosporidium prevalence among patients without colon neoplasia but with persistent gastrointestinal symptoms (OR: 4, CI: 1.65–9.6, P = 0.001). When the comparison was done against normal biopsies, the risk of infection increased 11-fold in the group of patients with colon adenocarcinoma (OR: 11.315, CI: 1.44–89.02, P = 0.003). Conclusions This is the first study performed in Lebanon reporting the prevalence of Cryptosporidium among patients with digestive cancer. These results show that Cryptosporidium is strongly associated with human colon cancer being maybe a potential etiological agent of this disease.
Collapse
Affiliation(s)
- Marwan Osman
- Institut Pasteur de Lille, Centre d’Infection et d’Immunité de Lille (CIIL), UMR CNRS 8204, INSERM U1019, Université de Lille, CHU de Lille, Biologie et Diversité des Pathogènes Eucaryotes Emergents (BDPEE), Lille, France
- Laboratoire Microbiologie Santé et Environnement (LMSE), Ecole Doctorale des Sciences et de Technologie, Faculté de Santé Publique, Université Libanaise, Tripoli, Lebanon
| | - Sadia Benamrouz
- Institut Pasteur de Lille, Centre d’Infection et d’Immunité de Lille (CIIL), UMR CNRS 8204, INSERM U1019, Université de Lille, CHU de Lille, Biologie et Diversité des Pathogènes Eucaryotes Emergents (BDPEE), Lille, France
- Ecologie et Biodiversité, Faculté de Gestion, Economie et Sciences (FGES), Université Catholique de Lille, Lille, France
| | - Karine Guyot
- Institut Pasteur de Lille, Centre d’Infection et d’Immunité de Lille (CIIL), UMR CNRS 8204, INSERM U1019, Université de Lille, CHU de Lille, Biologie et Diversité des Pathogènes Eucaryotes Emergents (BDPEE), Lille, France
| | - Martha Baydoun
- Institut Pasteur de Lille, Centre d’Infection et d’Immunité de Lille (CIIL), UMR CNRS 8204, INSERM U1019, Université de Lille, CHU de Lille, Biologie et Diversité des Pathogènes Eucaryotes Emergents (BDPEE), Lille, France
- BioMEMS, Université de Lille, CNRS, ISEN, UMR 8520 - IEMN, Lille, France
- BioGAP, groupe HEI-ISA-ISEN, Lille, France
| | - Emilie Frealle
- Institut Pasteur de Lille, Centre d’Infection et d’Immunité de Lille (CIIL), UMR CNRS 8204, INSERM U1019, Université de Lille, CHU de Lille, Biologie et Diversité des Pathogènes Eucaryotes Emergents (BDPEE), Lille, France
- Centre Hospitalier Régional et Universitaire de Lille & Faculté de Médecine de Lille, Université Lille Nord de France, Laboratoire de Parasitologie-Mycologie, Centre de Biologie et Pathologie, Lille, France
| | - Magali Chabe
- Institut Pasteur de Lille, Centre d’Infection et d’Immunité de Lille (CIIL), UMR CNRS 8204, INSERM U1019, Université de Lille, CHU de Lille, Biologie et Diversité des Pathogènes Eucaryotes Emergents (BDPEE), Lille, France
- Faculté des sciences pharmaceutiques et biologiques, Université Lille Nord de France, Département de Parasitologie–Mycologie, Lille, France
| | - Nausicaa Gantois
- Institut Pasteur de Lille, Centre d’Infection et d’Immunité de Lille (CIIL), UMR CNRS 8204, INSERM U1019, Université de Lille, CHU de Lille, Biologie et Diversité des Pathogènes Eucaryotes Emergents (BDPEE), Lille, France
| | - Baptiste Delaire
- Service d’Anatomie et de Cytologie Pathologiques, Groupement des Hôpitaux de l’Université Catholique de Lille, Lille, France
| | - Anne Goffard
- Molecular and Cellular Virology, University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019-UMR 8204-CIIL-Centre d’Infection et d’Immunité de Lille, Lille, France
| | - Albert Aoun
- Pathology Department, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Nawaf Jurdi
- Pathology Department, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
| | - Fouad Dabboussi
- Laboratoire Microbiologie Santé et Environnement (LMSE), Ecole Doctorale des Sciences et de Technologie, Faculté de Santé Publique, Université Libanaise, Tripoli, Lebanon
| | - Gael Even
- Genes Difussion, Douai, France-PEGASE-Biosciences, Lille, France
| | - Christian Slomianny
- Laboratory of Cell Physiology, INSERM U 1003, Université de Lille, Villeneuve d’Ascq, France
| | - Pierre Gosset
- Service d’Anatomie et de Cytologie Pathologiques, Groupement des Hôpitaux de l’Université Catholique de Lille, Lille, France
| | - Monzer Hamze
- Laboratoire Microbiologie Santé et Environnement (LMSE), Ecole Doctorale des Sciences et de Technologie, Faculté de Santé Publique, Université Libanaise, Tripoli, Lebanon
| | - Colette Creusy
- Service d’Anatomie et de Cytologie Pathologiques, Groupement des Hôpitaux de l’Université Catholique de Lille, Lille, France
| | - Eric Viscogliosi
- Institut Pasteur de Lille, Centre d’Infection et d’Immunité de Lille (CIIL), UMR CNRS 8204, INSERM U1019, Université de Lille, CHU de Lille, Biologie et Diversité des Pathogènes Eucaryotes Emergents (BDPEE), Lille, France
| | - Gabriela Certad
- Institut Pasteur de Lille, Centre d’Infection et d’Immunité de Lille (CIIL), UMR CNRS 8204, INSERM U1019, Université de Lille, CHU de Lille, Biologie et Diversité des Pathogènes Eucaryotes Emergents (BDPEE), Lille, France
- Département de la Recherche Médicale, Groupement des Hôpitaux de l’Institut Catholique de Lille, Faculté de Médecine et Maïeutique, Université Catholique de Lille, Lille, France
- * E-mail:
| |
Collapse
|
13
|
Baydoun M, Vanneste SB, Creusy C, Guyot K, Gantois N, Chabe M, Delaire B, Mouray A, Baydoun A, Forzy G, Chieux V, Gosset P, Senez V, Viscogliosi E, Follet J, Certad G. Three-dimensional (3D) culture of adult murine colon as an in vitro model of cryptosporidiosis: Proof of concept. Sci Rep 2017; 7:17288. [PMID: 29230047 PMCID: PMC5725449 DOI: 10.1038/s41598-017-17304-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Accepted: 11/19/2017] [Indexed: 01/12/2023] Open
Abstract
Cryptosporidium parvum is a major cause of diarrheal illness and was recently potentially associated with digestive carcinogenesis. Despite its impact on human health, Cryptosporidium pathogenesis remains poorly known, mainly due to the lack of a long-term culture method for this parasite. Thus, the aim of the present study was to develop a three-dimensional (3D) culture model from adult murine colon allowing biological investigations of the host-parasite interactions in an in vivo-like environment and, in particular, the development of parasite-induced neoplasia. Colonic explants were cultured and preserved ex vivo for 35 days and co-culturing was performed with C. parvum. Strikingly, the resulting system allowed the reproduction of neoplastic lesions in vitro at 27 days post-infection (PI), providing new evidence of the role of the parasite in the induction of carcinogenesis. This promising model could facilitate the study of host-pathogen interactions and the investigation of the process involved in Cryptosporidium-induced cell transformation.
Collapse
Affiliation(s)
- Martha Baydoun
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, France.,ISA-YNCREA Hauts-de-France, Lille, France.,Univ. Lille, CNRS, ISEN, UMR 8520 - IEMN, Lille, France
| | - Sadia Benamrouz Vanneste
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, France.,Laboratoire Ecologie et Biodiversité, Faculté de Gestion Economie et Sciences, Institut Catholique de Lille, Lille, France
| | - Colette Creusy
- Service d'Anatomie et de Cytologie Pathologiques, Groupement des Hopitaux de l'Institut Catholique de Lille (GHICL), Lille, France
| | - Karine Guyot
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, France
| | - Nausicaa Gantois
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, France
| | - Magali Chabe
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, France.,Faculté de Pharmacie, Univ. de Lille, Lille, France
| | - Baptiste Delaire
- Service d'Anatomie et de Cytologie Pathologiques, Groupement des Hopitaux de l'Institut Catholique de Lille (GHICL), Lille, France
| | - Anthony Mouray
- Plateforme d'Expérimentations et de Hautes Technologies Animales, Institut Pasteur de Lille, Lille, France
| | - Atallah Baydoun
- Department of Internal Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA.,Department of Internal Medicine, Louis Stokes VA Medical Center, Cleveland, OH, USA.,Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA
| | - Gerard Forzy
- Laboratoire de Biologie Médicale, Groupement des Hospitaux de l'Institut Catholique de Lille (GHICL), Lille, France
| | - Vincent Chieux
- Laboratoire de Biologie Médicale, Groupement des Hospitaux de l'Institut Catholique de Lille (GHICL), Lille, France
| | - Pierre Gosset
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, France.,Service d'Anatomie et de Cytologie Pathologiques, Groupement des Hopitaux de l'Institut Catholique de Lille (GHICL), Lille, France
| | - Vincent Senez
- Univ. Lille, CNRS, ISEN, UMR 8520 - IEMN, Lille, France
| | - Eric Viscogliosi
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, France
| | - Jérôme Follet
- ISA-YNCREA Hauts-de-France, Lille, France.,Univ. Lille, CNRS, ISEN, UMR 8520 - IEMN, Lille, France
| | - Gabriela Certad
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Centre d'Infection et d'Immunité de Lille, Lille, France. .,Département de la Recherche Médicale, Groupement des Hopitaux de l'Institut Catholique de Lille (GHICL), Faculté de Médecine et Maïeutique, Université Catholique de Lille, Lille, France.
| |
Collapse
|
14
|
Abd Elsalam M, Paul D, Baydoun M, A‘Gawad M. Using Sector Models to Optimize Field Development Planning. 2nd EAGE North African/Mediterranean Petroleum & Geosciences Conference & Exhibition 2005. [DOI: 10.3997/2214-4609-pdb.11.a21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
|